Post-traumatic stress disorder (PTSD) and childhood maltreatment (CMT: parental neglect; emotional, physical and sexual abuse) have been linked to bipolar disorder but they are also common in major depressive disorder (MDD). Our objective was to investigate their association with the bipolar spectrum and antidepressant treatment outcome in 482 outpatients with DSM-IV MDD treated in the Combining Medications to Enhance Depression Outcomes trial for 28 weeks. Bipolar spectrum score included age of onset <21 years, subthreshold hypomania (a period of elated or irritable mood with at least two concurrent hypomanic symptoms, which did not fulfill DSM criteria for hypomanic/manic episode) and depressive mixed state (DMX). PTSD subjects (n=107; 22%) had more severe depression (P<0.0001), work and social impairment (P=0.0031), comorbid anxiety disorders (P<0.0001) and increased suicidality (P=0.0003). Bipolar spectrum score was higher with PTSD comorbidity (P=0.0063) and childhood emotional abuse (P=0.0001). PTSD comorbidity was associated with residual suicidality (P=0.0218) after 6 weeks of antidepressant use whereas childhood emotional abuse (odds ratio (OR), 1.01–2.22), subthreshold hypomania (OR, 1.04–4.09) and DMX (OR, 1.00–4.19) were predictors of mood switch. These results corroborate the role of PTSD and childhood emotional abuse as markers of bipolar spectrum and prognostic factors during antidepressant treatment. Int Clin Psychopharmacol 37: 1–8 Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.

Keywords: bipolar spectrum, childhood maltreatment, hypomanic switch, mixed depression, post-traumatic stress disorder

Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy

Correspondence to Alessandro Serretti, MD, PhD, Department of Biomedical and Neuromotor Sciences, University of Bologna, Viale Carlo Pepoli 5, 40123 Bologna, Italy

Tel: +39 051 6584233; fax +39 051 521030; e-mail: alessandro.serretti@unibo.it

Received 9 August 2021 Accepted 20 September 2021

Introduction
On the basis of current diagnostic criteria, bipolar disorders are only identifiable by ascertaining manic or hypomanic episodes. This approach is not devoid of weaknesses (Nusslock and Frank, 2011). A first concern is that in bipolar patients the onset of mood activation is often preceded by a large number of depressive episodes, thus there is a lengthy time period from the point of illness onset to correct diagnosis. Second, milder, albeit clinically significant, bipolar spectrum syndromes would be included, by default, in major depressive disorder (MDD), with detrimental effects on illness course (e.g. manic switch and rapid cycling) related to inappropriate treatment. In the last few decades, a great research effort has allowed identifying reliable markers of bipolarity such as mixed depression [i.e. a major depressive episode (MDE) with few concurrent hypomanic symptoms] (Akiskal et al., 2005; Benazzi, 2005; Perugi et al., 2015) and subthreshold hypomanic episodes occurring outside depressive phases (Angst et al., 2003; Zimmermann et al., 2009; Serretti et al., 2021). Notwithstanding this progress, whenever information on prior manic or hypomanic episodes is not available, the correct identification of bipolar depression remains a challenge. In this context, post-traumatic stress disorder (PTSD) might deserve attention as a marker of bipolar spectrum. PTSD comorbidity involves up to one-third of patients with major depression (Green et al., 2006; Campbell et al., 2007) but several lines of evidence support its connection with bipolar disorder. For instance, it is known that individuals who have been exposed to traumatic experiences or complicated grief and exhibit PTSD manifestations are at increased risk of developing hypomanic symptoms (Dell’Osso et al., 2012). PTSD is actually one of the most frequent diagnoses in patients with bipolar disorder (Otto et al., 2004; Goldberg and Garno, 2005; Neria et al., 2008; Assion et al., 2009) and vice-versa (Hernandez et al., 2013; McLay et al., 2014). Moreover, the likelihood of PTSD in bipolar subjects is 4–5 times higher relative to patients with MDD (Dilsaver et al., 2007, 2008). Childhood maltreatment (CMT) – which includes parental neglect, emotional abuse, physical abuse and sexual abuse – is even more related to bipolar illness. In a meta-analysis individuals with bipolar disorder were 2.6 times more likely to report CMT compared to non-clinical controls (Palmier-Claus et al., 2016). Additionally, among bipolar subjects, those...
who had been exposed to CMT were more likely to experience their first episode earlier (Larsson et al., 2013) as well as to develop rapid cycling and suicidal behavior (Garno et al., 2005; Etain et al., 2013; Aas et al., 2014).

CMT has also been linked to suicidality. In the most comprehensive review, which analyzed over 260,000 individuals from 68 studies, CMT was associated with two-fold to three-fold increased risks for suicide ideation and attempts (Angelakis et al., 2019).

The aim of this study was to investigate the diagnostic and prognostic roles of PTSD and CMT in MDD, to disentangle their association with bipolar spectrum, the likelihood of mood activation and the persistence of suicidal tendency during antidepressant use.

Methods

Sample

This study was a secondary analysis of the Combining Medications to Enhance Depression Outcomes (CO-MED) trial, which was carried out at six primary care sites and nine psychiatric care centers across the USA (Rush et al., 2011). Eligible subjects were of age 18–75 years, with DSM IV-based MDD and HDRS scores ≥16. Exclusion criteria were psychotic depression or bipolar (DSM IV) illness and admission to psychiatric inpatient facilities. The CO-MED trial enrolled 665 sub-jects from March 2008 to September 2009. Our analysis involved 482 participants recruited until February 2009.

Ethical issue and informed consent

The CO-MED trial was conducted according to the Principles of Helsinki Declaration and its protocol was reviewed and approved by ethical committees at local recruitment sites (Rush et al., 2011). All subjects selected by clinicians were included in the screening phase after obtaining their written informed consent. This research group certifies that data collected for the CO-MED trial were exclusively used for scientific investigation. Before obtaining access to data, the objectives of our investigation were clearly described in the request form (Serretti et al., 2021).

Treatments

CO-MED was designed as a single-blind (participant only), placebo-controlled trial in which eligible subjects were randomly assigned to one of the following treatment arms: (1) escitalopram plus placebo; (2) bupropion SR plus escitalopram and (3) venlafaxine XR plus mirtazapine. The trial included a short-term (12 weeks) treatment followed by a continuation phase (weeks 12–28) (Rush et al., 2011).

Assessment

Sociodemographic characteristics were collected by means of a specific form including age, gender, ethnic group, education and monthly income (Rush et al., 2011). The Mini-International Neuropsychiatric Interview (M.I.N.I) (Sheehan et al., 1998) was used to validate the diagnosis of MDD and exclude psychotic and bipolar illness, to assess some clinical features such as chronic or recurrent depression, the number of past depressive episodes and age at onset of the first episode and to ascertain the lifetime occurrence of subthreshold hypomanic episodes (see below). Depressive episode was thoroughly assessed by administering the 30-item Inventory of Depressive Symptomatology-Clinician Rating (IDS-C30) (Corruble et al., 1999) and the 16-item Quick Inventory of Depressive Symptomatology (QIDS-C16) (Rush et al., 2003), the Converse Associated Symptoms Tracking (CAST) (Trivedi et al., 2011a) and Concise Health Risk Tracking (CHRt) (Trivedi et al., 2011b) scales, which respectively, assessed irritability and suicide propensity and ideation, the Altman Self-Rating Mania Scale (ASRM) (Altman, 1998) to ascertain intra-MDE hypomanic symptoms and the Work and Social Adjustment Scale (WSAS) (Mundt et al., 2002) to ascertain functional impairment. The individual assessment was completed by the Psychiatric Diagnostic Screening Questionnaire (PDSQ) (Zimmerman and Mattia, 1999), which investigated comorbid PTSD (post-traumatic scale ≥8) and anxiety disorders, and a questionnaire that was specifically developed to explore CMT subtypes (Medeiros et al., 2021).

Bipolar validators and bipolar spectrum score

The following variables were included among bipolar illness validators: (1) age at onset of first mood disorder episode (<21 years) (Benazzi, 2009); (2) per year recurrence of mood disorder episodes (Mazzarini et al., 2018); (3) lifetime occurrence of subthreshold hypomania: a period of elated or irritable mood with at least two concurrent hypomanic symptoms (MINI interview), which did not fulfill DSM criteria for hypomanic/manic episode (Angst et al., 2003; Serretti et al., 2021); (4) depressive mixed state (DMX) (Benazzi, 2001, 2008): an MDE with three or more hypomanic symptoms (ASMR), assessed before antidepressant treatment start. Subsequently, bipolar spectrum score was calculated as follows: A. age of onset <21 years: 1 point; + B. lifetime occurrence of subthreshold hypomania: 2 points; + C. DMX: 2 points.

Antidepressant treatment outcome

In prior CO-MED analysis, Medeiros and colleagues (2021) investigated the impact of CMT on antidepressant-treatment outcomes. Here, instead, we focused on PTSD comorbidity and analyzed its association with response (>50% decrease in QIDS score from baseline) and remission (QIDSs5) after six weeks of antidepressant use. In addition, we analyzed the association of PTSD and CMT with residual levels of suicide propensity and ideation (CHRt) as well as with mood activation (ASRM score ≥6) (Altman, 1998) occurring after ≥14 days of antidepressant use.

Statistical analysis

Univariate analyses were performed using Student’s t and Chi-square tests for continuous and categorical variables respectively; due to a large number of comparisons, the statistical significance threshold was conservatively
set at alpha = 0.025. Multivariate analysis was conducted by means of multiple regression and multiple logistic regression (MLR: $\chi^2 = 27.26; P < 0.0001$). Nevertheless, from the multivariate analysis, PTSD in major depression Olgiati and Serretti

### Results

Sample’s characteristics are summarized as follows: age: 43.15 ± 12.46 years; males: 144 (30%); depression severity (IDS-C$_{30}$): 38.63 ± 9.13. PTSD and CMT were reported by 107 (22%) and 260 (54%) patients, respectively. Subjects with PTSD endorsed a larger number of CMT events than their counterpart without PTSD (PTSD: 1.92 ± 1.56; no PTSD: 1.13 ± 1.35; $t = 4.71; P < 0.0001$); in fact, they were more often victims of parental neglect (PTSD: 42/107; no PTSD: 67/375; $\chi^2 = 21.87; P < 0.0001$) and childhood physical abuse (PTSD: 42/107; no PTSD: 67/375; $\chi^2 = 21.75; P < 0.0001$). Nevertheless, from the multivariate analysis of CMT subtypes, physical abuse was the only independent predictor of PTSD comorbidity (MLR: $\chi^2 = 27.26; P < 0.0001$: OR, 1.89; 95% CI, 1.04–3.83).

### Post-traumatic stress disorder comorbidity and depression severity

Comparisons between PTSD and no PTSD groups are displayed in Table 1. Subjects with PTSD were characterized by higher depression scores at baseline (IDS-C$_{30}$) ($t = 4.10; P < 0.00001$), greater work and social impairment ($t = 2.97; P = 0.0031$), increased suicidality (CHRT suicide propensity scale: $t = 3.63; P = 0.0003$; CHRT suicide risk scale: $t = 2.99; P = 0.0029$) and more anxiety disorder comorbidity (panic disorder: $t = 9.69; P < 0.00001$; generalized anxiety: $t = 8.04; P < 0.00001$; obsessive compulsive disorder (OCD): $t = 8.03; P < 0.00001$; social phobia: $t = 5.86; P < 0.0001$) (Table 1). Their symptom profile included higher levels of negative self-outlook ($t = 3.08; P = 0.0022$), anxious mood ($t = 3.15; P = 0.0017$), difficulty in falling asleep ($t = 4.26; P < 0.0001$), middle nocturnal insomnia ($t = 3.29; P = 0.0012$) and poor concentration ($t = 2.71; P = 0.0070$). MLR analysis identified seven independent predictors of PTSD comorbidity: overall depression score (OR, 0.89–0.98), negative self-outlook (OR, 1.01–1.96), difficulty in falling asleep (OR, 1.00–1.61), middle nocturnal insomnia (OR, 1.01–1.77) and comorbid panic disorder (OR, 1.07–1.23), generalized anxiety (OR, 1.07–1.29) and OCD (OR, 1.06–1.47).

### Post-traumatic stress disorder comorbidity and bipolar features

The mean age at depression onset was 23.35 ± 13.50 years but in 262 subjects (54%) the first episode occurred before 21 years of age. 68 subjects (14%) met the criteria for DMX and 48 (10%) for subthreshold hypomania. Comparisons of bipolar features by PTSD classifier are displayed in Table 2. The PTSD group was found to differ from individuals without PTSD in terms of younger age at depression onset ($t = 2.48; P = 0.0136$), greater lifetime presence of subthreshold hypomania (Chi-square = 5.39; $P = 0.020$) and higher bipolar spectrum score ($t = 2.77; P = 0.0063$). Conversely, the distribution of DMX was not statistically different between the two groups. Among bipolar spectrum symptoms, irritability (CAST: $t = 3.86; P = 0.0002$), increased taltalkativeness ($t = 2.86; P = 0.005$) and reduced need for sleep ($t = 2.67; P = 0.0084$) showed the strongest association with PTSD. By performing MLR analysis, bipolar spectrum score emerged as an independent predictor of PTSD (OR, 1.05–1.54) along with irritability (OR, 1.14–3.76), difficulty in falling asleep (OR, 1.03–1.54) and middle nocturnal insomnia (OR, 1.02–1.61) (Table 2). The association between bipolar spectrum score and PTSD was no more significant (OR, 0.99–1.48) when CMT subtypes were added to other variables; thus, the new PTSD predictors

### Table 1 Patients with and without post-traumatic stress disorder

| Predictors | OR (95% CI) | With PTSD (N=107) | Without PTSD (N=375) | P |
|------------|-------------|-------------------|----------------------|---|
| Age        |             | 42.2 ± 11.2       | 43.4 ± 12.8          | 0.3902 |
| Gender     |             | 33 (0.30)         | 112 (0.29)           | 0.9990 |
| Ethnicity  |             | 67 (0.63)         | 254 (0.68)           | 0.8380 |
| Education  |             | 13.4 ± 2.5        | 13.8 ± 3.2           | 0.1346 |

*Significant $P < 0.01$.  
*Multiple logistic regression analysis: Chi-square = 85.09; df = 13; P < 0.00001  
GAD, generalised anxiety; OCD, obsessive compulsive disorder.

### Sociodemographic characteristics and depression features.

*Only statistically significant predictors are shown.

CHRT, Concise Health Risk Tracking; GAD, generalised anxiety; IDS-C$_{30}$-30-item Inventory of Depressive Symptomatology-Clinician Rating; OCD, obsessive compulsive disorder; PTSD, post-traumatic stress disorder; PDSQ, Psychiatric Diagnostic Screening Questionnaire.
became irritability (OR, 1.12–3.81), difficulty in falling asleep (OR, 1.02–1.55), middle nocturnal insomnia (OR, 1.01–1.61) and childhood physical abuse (OR, 1.05–3.63) (Table 2).

**Childhood maltreatment exposure and bipolar spectrum**

Our research sample more often reported childhood exposure to emotional abuse (N = 212; 44%) and parental neglect (N = 194; 40%), whereas physical (N = 109; 23%) and sexual (N = 115; 24%) abuse were less common. All CMT subtypes, except for physical abuse (t = 1.71; P = 0.0875), were associated with higher bipolar spectrum scores at univariate level (emotional abuse: t = 4.32; P < 0.0001; neglect: t = 3.74; P = 0.0002; sexual abuse: t = 2.45; P = 0.0146). Multiple regression analysis, however, identified childhood emotional abuse as the only independent predictor of the bipolar spectrum (beta = 0.216; t = 3.90; P = 0.0001) (Table 3).

**Antidepressant treatment outcome and mood activation switch**

A total of 395 patients (82%) completed 6 week period of antidepressant use. Of them, 183 subjects (46%) were classified as responders and 117 (30%) achieved remission. None of the two outcome definitions was associated with PTSD comorbidity (Response: PTSD = 35/80 no PTSD = 148/315; χ² = 0.268; P = 0.605; Remission: PTSD = 18/80 no PTSD = 99/315; χ² = 2.391; P = 0.122), neither after controlling for depression severity (MLR χ² = 8.43; P = 0.0162; remission: OR, 0.41–1.52). Instead, patients with PTSD comorbidity showed higher levels of residual suicide propensity (CHRT) than their counterparts without PTSD (P = 0.0092), similar to individuals who reported histories of parental neglect (P = 0.0053) and emotional abuse (P = 0.039) during childhood (Table 4). However, after controlling for baseline CHRT scores, only PTSD comorbidity was confirmed to be correlated with suicide propensity at week 6 (multiple regression: F = 36.51; P < 0.0001; PTSD: beta = 0.107; P = 0.0218) (Table 4). Mood activation was found to occur in 204 out of 425 subjects (48%) who had been receiving antidepressant treatments for at least 14 days. The mood activation group included more cases with subthreshold hypomania (OR, 1.04–4.09), DMX (OR, 1.00–4.19) and childhood emotional abuse (OR, 1.01–2.22) were independently associated with mood activation risk (Table 5).

**Discussion**

In our sample, about one in five patients had PTSD comorbidity. This figure was distant from 50 to 70% reported in Veteran outpatients (Zisook et al., 2016; Mohamed et al., 2020) and socioeconomically disadvantaged groups (Grote et al., 2016), but substantially similar to 33–36% displayed in other clinical samples (Green et al., 2006; Campbell et al., 2007). Instead, the prevalence of PTSD was significantly lower in the Sequenced

### Table 2 Post-traumatic stress disorder correlates: bipolar features, irritability, insomnia and childhood maltreatment

| Predictor                                      | With PTSD (N = 107) | Without PTSD (N = 375) | P      |
|------------------------------------------------|---------------------|------------------------|--------|
| Age of depression onset                        | 20.5 ± 13.6         | 24.2 ± 13.4            | 0.0136*|
| N. episodes/illness years                      | 0.5 ± 1.2           | 0.3 ± 0.6              | 0.1186 |
| Depressive mixed state (DMX)                   | 20 (0.19)           | 45 (0.12)              | 0.0742 |
| Subthreshold hypomania                         | 17 (0.16)           | 31 (0.08)              | 0.0204*|
| Bipolar spectrum score                         | 1.3 ± 1.2           | 0.9 ± 1.0              | 0.0063*|
| Irritability (CAST)                            | 0.9 ± 0.4           | 0.7 ± 0.5              | 0.0002*|
| Increased talkativeness (ASRM)                 | 0.7 ± 1.1           | 0.3 ± 0.7              | 0.0050*|
| Reduced need for sleep (ASRM)                  | 0.8 ± 1.3           | 0.4 ± 0.9              | 0.0084*|
| Increased activity (ASRM)                      | 0.3 ± 0.9           | 0.1 ± 0.5              | 0.0274 |

Multiple logistic regression analysis (overlapping symptoms between PTSD and bipolar disorder): Chi-square = 37.73; df = 5; P < 0.0001

### Table 3 Childhood maltreatment and bipolar spectrum score

| Predictor                                      | Present | Absent | P      |
|------------------------------------------------|---------|--------|--------|
| N                                              | Mean ± SD | Mean ± SD |        |
| Childhood parental neglect                     | 0.73 ± 0.12 | 0.3 ± 0.9 | 0.0162 |
| Childhood emotional abuse                      | 0.21 ± 0.17 | 0.2 ± 0.15 | 0.73   |
| Childhood physical abuse                       | 0.28 ± 0.2  | 0.3 ± 0.25 | 0.101  |
| Childhood sexual abuse                         | 0.35 ± 0.3  | 0.4 ± 0.35 | 0.107  |

Multiple regression: F = 7.37; df = 3; P = 0.0001

*Biological spectrum score: age of onset < 21 years (1 point) + subthreshold hypomania (2 points) + DMX (2 points).

DMX, depressive mixed state (see manuscript).
Table 4  Antidepressant treatment outcome (week 6) (N=395)

|                      | With PTSD N=80 | Without PTSD N=315 | P  |
|----------------------|----------------|---------------------|----|
| Response             |                |                     |    |
| 35 (0.44)            | 148 (0.47)     | 0.6040              |    |
| Remission            | 18 (0.22)      | 99 (0.31)           | 0.1220 |
| Suicidality propensity | 11.15 ± 8.55  | 8.59 ± 7.54         | 0.0092* |
| Suicidality ideation | 1.41 ± 2.26    | 1.03 ± 1.81         | 0.1669 |
| N=152                | N=241          |                     |    |
| Suicide propensity   | 10.47 ± 8.10   | 8.23 ± 7.50         | 0.0059* |
| Suicide ideation     | 1.31 ± 2.10    | 0.98 ± 1.77         | 0.1049 |
| Emotional abuse      |                | No abuse            |    |
| N=168                | N=225          |                     |    |
| Suicide propensity   | 10.43 ± 8.33   | 8.10 ± 7.25         | 0.0093* |
| Suicide ideation     | 1.38 ± 2.25    | 0.90 ± 1.58         | 0.0182* |
| Physical abuse       |                | No abuse            |    |
| N=84                 | N=311          |                     |    |
| Suicide propensity   | 10.55 ± 7.71   | 8.70 ± 7.80         | 0.0546 |
| Suicide ideation     | 1.44 ± 2.15    | 1.01 ± 1.84         | 0.0982 |
| Sexual abuse         |                | No abuse            |    |
| N=93                 | N=302          |                     |    |
| Suicide propensity   | 10.44 ± 7.64   | 8.68 ± 7.82         | 0.0572 |
| Suicide ideation     | 1.22 ± 1.89    | 1.07 ± 1.92         | 0.5233 |

Multiple regression: \( F=36.51 \)  df=5 \(<0.0001\)

Dependent variable: predictors: emotional abuse is excluded (weakest predictor).

Suicidality propensity (baseline) Beta=0.558 \(<0.0001*\)

PTSD Beta=0.108 0.0207*

Neglect Beta=0.024 0.8528

Physical abuse Beta=0.106 0.0504

Sexual abuse Beta=0.027 0.5829

Role of PTSD and childhood maltreatment. CMT: parental neglect; sexual abuse; physical abuse; emotional abuse.

CMT, childhood maltreatment; PTSD, post-traumatic stress disorder.

Treatment Alternatives to Relieve Depression study (STAR*D), which only identified 122 cases from 2280 participants (5%) (Steiner et al., 2017). Such a difference was not related to PTSD assessment, which was conducted via PDSQ administration as well, but it could reflect the larger proportion of patients (54%) in our sample who were victims of maltreatment during childhood and, consequently, exposed to traumatization.

Diagnostic role of post-traumatic stress disorder and childhood emotional abuse as markers of subthreshold bipolarity

A clear-cut result of our study was to associate PTSD and childhood emotional abuse with a variety of bipolar validators assessed lifetime (Angst et al., 2003; Benazzi, 2009; Zimmermann et al., 2009; Mazzarini et al., 2018) and during a single MDE (Benazzi, 2001, 2005, 2008; Akiskal et al., 2005; Perugi et al., 2015). These findings are largely consistent with epidemiological data that suggest high levels of diagnostic comorbidity between PTSD and bipolar disorder (Otto et al., 2004; Graves et al., 2007; Neria et al., 2008; Hernandez et al., 2013; McLay et al., 2014). Moreover, prior to ours, other studies have displayed a correlation between childhood adversity and bipolar features in major depressed patients (Park, 2017). It is plausible that childhood traumas and maltreatment are not simply more widespread among subjects with bipolar disorders (Janiri et al., 2015; Palmieri-Claus et al., 2016) but, rather, risk factors for bipolar illness (Quide et al., 2020). The comorbidity between PTSD and bipolar disorder could be explained by the overlap of some symptoms between these conditions. In particular sleep disturbance, difficulty concentrating, increased risk-taking behavior and irritability are often reported in patients with PTSD and bipolar disorders (Cogan et al., 2021) and they also represent the typical profile of mixed depression (Perugi et al., 2015; Brancati et al., 2019). Therefore a valuable result of this study was to demonstrate that control for irritability, insomnia and poor concentration did not modify the association between bipolar risk score and PTSD. This would suggest that the co-occurrence of PTSD and bipolar spectrum disorder might be true comorbidity rather than a mere artifact, although there is a need for further studies to corroborate this hypothesis. However, if experiences of CMT were added to irritability and insomnia, the association between bipolar risk score and PTSD was no more significant. Overall these results seem to indicate that the association between bipolar spectrum and PTSD could be at least in part mediated by CMT. Nevertheless, further studies are necessary to ascertain the effectiveness of assessing PTSD symptoms and childhood maltreatment in patients with DSM unipolar depression in order to improve the identification of bipolar spectrum disorders.

Prognostic impact of post-traumatic stress disorder and childhood emotional abuse

We found that the presence of PTSD was associated with more severe depressive symptoms, notably higher negative self-outlook, anxiety and insomnia, work and social impairment and increased suicidal tendency. This

Table 5  Predictors of mood activation (ASRM ± 6) switch after at least 14 days of treatment (N=425 patients)

|                      | Switch N=204 | No switch N=221 | P  |
|----------------------|-------------|----------------|----|
| Depressive mixed state (DMX) (N=37) | 24 (0.12) | 13 (0.06) | 0.0308 |
| Subthreshold hypomania (N=42) | 28 (0.14) | 14 (0.06) | 0.0103* |
| PTSD (N=85) | 46 (0.22) | 39 (0.18) | 0.2070 |
| Childhood parental neglect (N=169) | 89 (0.44) | 80 (0.36) | 0.1179 |
| Childhood emotional abuse (N=186) | 101 (0.49) | 85 (0.38) | 0.0217* |
| Childhood physical abuse (N=94) | 50 (0.24) | 44 (0.19) | 0.2538 |
| Childhood sexual abuse (N=104) | 52 (0.25) | 52 (0.23) | 0.6386 |

Multiple logistic regression (tested predictors with univariate \( P\leq0.1\); Chi-square: 14.50 df: 3; \( P=0.0023\)

OR [95% CI]

Depressive mixed state (DMX): 2.05 (1.00–4.19)

Subthreshold hypomania: 2.06 (1.04–4.09)

Childhood emotional abuse: 1.45 (1.01–2.22)

ASRM, Altman Self-Rating Mania Scale (Altman, 1998); CI, confidence interval; OR, odds ratio; PTSD, post-traumatic stress disorder.
picture was consistent with prior studies suggesting that subjects with comorbid major depression and PTSD might have more psychopathological manifestations as well as a higher suicide risk than those with either condition alone (Morina et al., 2013). Moreover, our findings mirrored those emerging from the STAR*D study, which displayed the impact of PTSD comorbidity on depression severity and functional impairment as well (Steiner et al., 2017). As baseline clinical severity was found to negatively affect antidepressant treatment outcomes (Friedman et al., 2012), we expected that PTSD comorbidity was associated with a less favorable antidepressant response. Such a correlation had been documented in STAR*D sample (Steiner et al., 2017). Conversely, we failed to demonstrate any association between PTSD and antidepressant-related outcomes. This result was in line with a recent study, based on CO-MED data like the present one, in which exposure to CMT had no impact on antidepressant response (Medeiros et al., 2021). Nevertheless, PTSD might exert a negative prognostic influence on major depression. Indeed, in our sample, PTSD group was characterized by higher levels of the residual propensity for suicidal behavior after acute antidepressant treatment and this association was confirmed even accounting for the higher degree of suicidality reported at baseline.

Another outcome variable analyzed in the current study was the new onset of mood activation symptoms during antidepressant use. The occurrence of hypomanic symptoms within a depressive episode of unipolar disorder was already investigated using CO-MED sample (Jha et al., 2018). In that study, patients who endorsed hypomanic symptomatology were characterized by lower remission rates with escitalopram monotherapy and venlafaxine plus mirtazapine combination. Instead, our results corroborated the role of intra-MDE hypomanic symptoms and sub-threshold hypomanic episodes in predicting mood switch during antidepressant therapy. Interestingly, a similar correlation with mood activation was shown by childhood emotional abuse. These findings are intriguing and provide new evidence about predictors of mood activation in apparently unipolar depression (DelBello et al., 2003; Celik et al., 2016).

Strengths and limitations
This study analyzed in detail depressive symptomatology and bipolar features using both cross-sectional and longitudinal approaches. Axis I comorbidities were also carefully assessed. Hence, it was possible to disentangle the effect of several potential confounding variables while investigating the association between PTSD comorbidity and bipolar spectrum. The onset of mood activation during antidepressant treatment is a concern for clinicians and our study provided some cues to predict this risk. On the other hand, the main limitations are related to the post hoc nature of our analysis and to the retrospective approach used to investigate a large number of variables (e.g. onset of the first depressive episode; lifetime occurrence of subthreshold hypomania; CMT, etc). Moreover, common symptoms of mixed depression such as thought racing, distractibility or reckless activity could not be assessed using the ASMR scale, thus the prevalence of DMX could have been underestimated as well as some reliable bipolar validators (e.g. family history) were not available. Finally, there is evidence that the effects of childhood emotional abuse on suicidality are at least in part mediated by emotional abuse and depressive symptoms experienced in adulthood (Lee, 2015). Therefore, a caveat of this study was that it could analyze emotional abuse during childhood but not re-victimization in adult age.

Conclusion
Maltreatment experiences occurring in childhood and PTSD symptoms in adult age are commonly reported by subjects with MDD. Their presence is associated with severe forms of depression and, as suggested by current data, they might be putative markers of bipolar spectrum. Therefore, PTSD symptoms and CMT should be carefully assessed in all patients who endorse an MDE before choosing pharmacological treatment, in order to minimize risk for a mood activation switch.

Acknowledgements
We thank the NIMH for having had the possibility of analyzing their data on the COMED sample. We also thank the authors of previous publications in this dataset, and foremost, we thank the subjects and their families who accepted to be enrolled in the study. Data and biomaterials were obtained from the limited access datasets distributed from the NIH. The ClinicalTrials.gov identifier is NCT00590863.

Data were obtained for analysis from the National Institute of Mental Health, Bethesda, Maryland, US (Request ID 5ce26a95712d8). The CO-MED trial was conducted according to the Principles of the Helsinki Declaration. The study protocol was reviewed and approved by ethical committees at local recruitment sites. All subjects selected by clinicians were included in the screening phase after obtaining their written informed consent. This research group certifies that data collected for the CO-MED trial were exclusively used for scientific investigation. Before obtaining access to data, the objectives of our investigation were clearly described in the request form.

A.S. and P.O. conceived the study; P.O. performed the analyses and drafted the manuscript; A.S. revised and interpreted the results, discussed the findings and drafted the final version of the article.

Conflicts of interest
A.S. is or has been a consultant to or has received honoraria or grants unrelated to the present work from Abbott, Abbvie, Angelini, Astra Zeneca, Clinical Data, Boheringer, Bristol...
Myers Squibb, Eli Lilly, GlaxoSmithKline, Innovapharma, Italfarma, Janssen, Lundbeck, Naurex, Pfizer, Polifarma, Sanofi, Servier and Taliaz. P.O. has no conflicts of interest.

References

Aas M, Etaan B, Belliver R, Henry C, Lagerberg T, Ringen A, et al. (2014). Additive effects of childhood abuse and cannabis abuse on clinical expressions of bipolar disorders. Psychol Med 44:1653–1662.

Akisal HS, Benazzi F, Perugi G, Rihmer Z (2005). Agitated “unipolar” depression re-conceptualized as a depressive mixed state: implications for the antide- pressant-suicide controversy. J Affect Disord 85:245–258.

Altman E (1998). Rating scales for mania: is self-rating reliable? J Affect Disord 50:283–286.

Angelakis I, Gillespie EL, Panagioti M (2019). Childhood maltreatment and adult suicidality: a comprehensive systematic review with meta-analysis. Psychol Med 49:1057–1078.

Angst J, Gamma A, Benazzi F, Aidoacic V, Eich D, Rössler W (2003). Toward a re-definition of subthreshold bipolarity: epidemiology and proposed criteria for bipolar-II, minor bipolar disorders and hypomania. J Affect Disord 73:133–146.

Assion HJ, Brune N, Schmidt N, Aubel T, Edel MA, Basilowski M, et al. (2009). Trauma exposure and post-traumatic stress disorder in bipolar disorder. Soc Psychiatry Psychiatr Epidemiol 44:1041–1050.

Benazzi F (2001). Depressive mixed state: testing different definitions. Psychiatr Clin Neurosci 55:647–652.

Benazzi F (2009). Classifying mood disorders by age-at-onset instead of polarity. Prog Neuropsychopharmacol Biol Psychiatry 33:86–93.

Benazzi F, Akisal H (2005). Irritable-hostile depression: further validation as a bipolar depressive mixed state. J Affect Disord 84:197–207.

Benazzi F (2005). Mixed depression: a clinical marker of bipolar-II disorder. Prog Neuropsychopharmacol Biol Psychiatry 29:267–274.

Benazzi F (2008). Reviewing the diagnostic validity and utility of mixed depression (depressive mixed states). Eur Psychiatry 23:40–48.

Brancati GE, Veta E, Azorin JM, Angst J, Bowden CL, Mosolov S, et al.; BRIDGE-II–Mix Study Group. (2019). The role of overlapping excitory symptoms in major depression: are they relevant for the diagnosis of mixed state? J Psychiatr Res 115:151–157.

Campbell DG, Felker BL, Liu CF, Yano EM, Kirchner JE, Chan D, et al. (2007). Prevalence of depression-PTSD comorbidity: implications for clinical practice guidelines and primary care-based interventions. J Gen Intern Med 22:711–718.

Çelik SB, Buckatepe GE, Ulaşdaş A, Bulut IJ, Erdem Ö, Altınbaş K (2016). Screening mixed depression and bipolarity in the postpartum period at a primary health care center. Compr Psychiatry 74:57–62.

Cogan GM, Paquet CB, Lee JT, Miller KE, Crowley MD, Davis JL (2021). Differentiating the symptoms of posttraumatic stress disorder and bipolar disorders in adults: utilizing a trauma-informed assessment approach. Clin Psychol Psychother 28:251–260.

Corbelle E, Legrand JM, Duret C, Charles G, Guelfi JD (1999). IDS-C and BDI-II in assessing depression. J Affect Disord 53:197–207.

Cristinale GC, Pruett WL, Rush AJ, Minhajuddin A, Cayzy AH, Patel SS, et al. (2021). Impact of childhood maltreatment on outcomes of antidepressant medication in chronic and/or recurrent depression. J Affect Disord 319:39–45.

Dilsaver SC, Benazzi F, Akisal HS, Akisal KK (2007). Post-traumatic stress disorder in patients with bipolar disorder: a retrospective study. J Clin Psychiatry 68:595–610.

Dilsaver SC, Benazzi F, Akisal HS, Akisal KK (2007). Post-traumatic stress disorder in patients with bipolar disorder: a retrospective study. J Clin Psychiatry 68:595–610.

Dilsaver SC, Benazzi F, Akisal HS, Akisal KK (2007). Post-traumatic stress disorder in patients with bipolar disorder: a retrospective study. J Clin Psychiatry 68:595–610.

Dilsaver SC, Benazzi F, Akisal HS, Akisal KK (2007). Post-traumatic stress disorder in patients with bipolar disorder: a retrospective study. J Clin Psychiatry 68:595–610.

Dilsaver SC, Benazzi F, Akisal HS, Akisal KK (2007). Post-traumatic stress disorder in patients with bipolar disorder: a retrospective study. J Clin Psychiatry 68:595–610.

Dilsaver SC, Benazzi F, Akisal HS, Akisal KK (2007). Post-traumatic stress disorder in patients with bipolar disorder: a retrospective study. J Clin Psychiatry 68:595–610.

Dilsaver SC, Benazzi F, Akisal HS, Akisal KK (2007). Post-traumatic stress disorder in patients with bipolar disorder: a retrospective study. J Clin Psychiatry 68:595–610.

Dilsaver SC, Benazzi F, Akisal HS, Akisal KK (2007). Post-traumatic stress disorder in patients with bipolar disorder: a retrospective study. J Clin Psychiatry 68:595–610.

Dilsaver SC, Benazzi F, Akisal HS, Akisal KK (2007). Post-traumatic stress disorder in patients with bipolar disorder: a retrospective study. J Clin Psychiatry 68:595–610.
Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Amow B, Klein DN, et al. (2003). The 16-item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. *Biol Psychiatry* **54**: 573–583.

Serretti A, De Ronchi D, Olgiati P (2021). Irritable mood and subthreshold hypomanic episodes correlate with more severe major depression. *Neuropsychobiology* **18**:1–11.

Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. (1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. *J Clin Psychiatry* **59** (suppl 20):22–33.

Steiner AJ, Boulos N, Mirocha J, Wright SM, Collison KL, IsHak WW (2017). Quality of life and functioning in comorbid posttraumatic stress disorder and major depressive disorder after treatment with citalopram monotherapy. *Clin Neuropharmacol* **40**:16–23.

Trivedi MH, Wisniewski SR, Morris DW, Fava M, Gollan JK, Warden D, et al. (2011). Concise Health Risk Tracking scale: a brief self-report and clinician rating of suicidal risk. *J Clin Psychiatry* **72**:757–764.

Trivedi MH, Wisniewski SR, Morris DW, Fava M, Kurian BT, Gollan JK, et al. (2011). Concise Associated Symptoms Tracking scale: a brief self-report and clinician rating of symptoms associated with suicidality. *J Clin Psychiatry* **72**: 765–774.

Zimmermann P, Mattia JJ (1999). The reliability and validity of a screening questionnaire for 13 DSM-IV axis I disorders (the psychiatric diagnostic screening questionnaire) in psychiatric outpatients. *J Clin Psychiatry* **60**:677–683.

Zimmermann P, Brückl T, Nocon A, Pfister H, Lieb R, Wittchen HU, et al. (2009). Heterogeneity of DSM-IV major depressive disorder as a consequence of subthreshold bipolarity. *Arch Gen Psychiatry* **66**:1341–1352.

Zisook S, Tal I, Weingart K, Hicks P, Davis LL, Chen P, et al. (2018). Characteristics of U.S. veteran patients with major depressive disorder who require “next-step” treatments: a VAST-D report. *J Affect Disord* **206**:232–240.